We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+37.02%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$390M
AUM Growth
+$12.6M
Cap. Flow
-$64M
Cap. Flow %
-16.4%
Top 10 Hldgs %
30.29%
Holding
100
New
16
Increased
29
Reduced
38
Closed
17

Top Buys

Rank Stock Value
1
SDGR icon
Schrodinger
SDGR
+$6.67M
2
ARWR icon
Arrowhead Research
ARWR
+$4.3M
3
DXCM icon
DexCom
DXCM
+$4.27M
4
AVTR icon
Avantor
AVTR
+$3.89M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$3.76M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$12.7M
2
MRK icon
Merck
MRK
+$10.4M
3
AXNX
Axonics, Inc. Common Stock
AXNX
+$9.03M
4
MASI
Masimo
MASI
+$8.26M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$6.12M

Sector Composition

Rank Sector Weight
1 Healthcare 92.05%
2 Technology 1.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STRO icon
26
Sutro Biopharma
STRO
$353M
$5.79M 1.48%
26,665
+5,665
+27% +$938K
IMUX icon
27
Immunic
IMUX
$217M
$5.61M 1.44%
36,669
-3,333
-8% -$599K
ITMR
28
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$5.61M 1.44%
282,327
+1,627
+0.6% +$32.5K
XENE icon
29
Xenon Pharmaceuticals
XENE
$6.31B
$5.56M 1.43%
361,689
-103,136
-22% -$1.21M
BBIO icon
30
BridgeBio Pharma
BBIO
$16.4B
$5.42M 1.39%
76,143
+915
+1% +$44.1K
NUAN
31
DELISTED
Nuance Communications, Inc.
NUAN
$5.1M 1.31%
115,662
-44,413
-28% -$1.68M
ALNY icon
32
Alnylam Pharmaceuticals
ALNY
$30B
$4.7M 1.2%
36,161
+5,298
+17% +$707K
EW icon
33
Edwards Lifesciences
EW
$53.6B
$4.62M 1.18%
50,584
-71,947
-59% -$5.97M
INFU icon
34
InfuSystem Holdings
INFU
$244M
$4.54M 1.16%
241,511
+8,576
+4% +$129K
SILK
35
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$4.27M 1.09%
67,854
-52,161
-43% -$3.24M
IONS icon
36
Ionis Pharmaceuticals
IONS
$9.39B
$4.26M 1.09%
+75,418
New +$3.76M
AVTR icon
37
Avantor
AVTR
$9.42B
$4.25M 1.09%
+150,872
New +$3.89M
KRMD icon
38
KORU Medical Systems
KRMD
$152M
$4.22M 1.08%
701,259
+70,033
+11% +$392K
AXGN icon
39
Axogen
AXGN
$2.67B
$4.13M 1.06%
230,509
+105,509
+84% +$1.55M
BCRX icon
40
BioCryst Pharmaceuticals
BCRX
$2.71B
$4.01M 1.03%
538,370
-262,370
-33% -$1.35M
KDMN
41
DELISTED
Kadmon Holdings, Inc.
KDMN
$3.88M 0.99%
934,364
+59,214
+7% +$234K
NVAX icon
42
Novavax
NVAX
$1.31B
$3.85M 0.99%
34,498
+16,998
+97% +$1.81M
IDXX icon
43
Idexx Laboratories
IDXX
$45B
$3.8M 0.97%
7,593
+93
+1% +$41.6K
GOSS icon
44
Gossamer Bio
GOSS
$86.8M
$3.39M 0.87%
+350,779
New +$3.46M
STXS icon
45
Stereotaxis
STXS
$139M
$3.3M 0.84%
647,543
+3,730
+0.6% +$15.3K
MRSN
46
DELISTED
Mersana Therapeutics
MRSN
$3.27M 0.84%
4,921
-682
-12% -$379K
ONEM
47
DELISTED
1Life Healthcare
ONEM
$3.27M 0.84%
+75,000
New +$2.56M
HCAT icon
48
Health Catalyst
HCAT
$135M
$3.27M 0.84%
+75,000
New +$2.77M
ABBV icon
49
AbbVie
ABBV
$440B
$3.21M 0.82%
30,000
-45,008
-60% -$4.33M
MRVI icon
50
Maravai LifeSciences
MRVI
$861M
$3.09M 0.79%
+110,276
New +$3.07M
1
2
3 4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q4 2020 Portfolio in Review

As of Q4 2020, Parkman Healthcare Partners held 100 positions worth $390M, up 3.3% from $378M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Parkman Healthcare Partners withdrew a net $64M in Q4 2020, closing 17 positions and reducing 38 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $12.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier, followed by Technology.

Against the trend, Parkman Healthcare Partners opened a new position in Avantor worth $4.25M.

  • Parkman Healthcare Partners's largest Q4 2020 buy was Avantor: 150,872 shares worth $4.25M.
  • Parkman Healthcare Partners added most to Schrodinger in Q4 2020, an estimated $6.67M increase.
  • Parkman Healthcare Partners's biggest Q4 2020 reduction was Edwards Lifesciences, cutting an estimated $5.97M.
  • Parkman Healthcare Partners fully exited Neurocrine Biosciences in Q4 2020, selling an estimated $12.7M.
  • Parkman Healthcare Partners's ten largest holdings make up 30% of its $390M portfolio in Q4 2020.
  • Parkman Healthcare Partners opened 16 new positions and closed 17 in Q4 2020.
  • Parkman Healthcare Partners's portfolio value rose 3.3% quarter-over-quarter to $390M.

Based on Parkman Healthcare Partners's 13F filing for Q4 2020, filed 12 Feb 2021.